Eli Lilly and Company (NYSE:LLY) Shares Purchased by MONECO Advisors LLC

MONECO Advisors LLC grew its position in shares of Eli Lilly and Company (NYSE:LLY) by 8.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,023 shares of the company’s stock after purchasing an additional 247 shares during the quarter. MONECO Advisors LLC’s holdings in Eli Lilly and Company were worth $1,762,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Simon Quick Advisors LLC raised its position in Eli Lilly and Company by 10.5% during the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock worth $1,706,000 after buying an additional 278 shares during the last quarter. Clear Harbor Asset Management LLC purchased a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $363,000. Terril Brothers Inc. boosted its stake in shares of Eli Lilly and Company by 113.2% in the fourth quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock valued at $471,000 after buying an additional 429 shares in the last quarter. Hartline Investment Corp grew its holdings in Eli Lilly and Company by 1.1% during the fourth quarter. Hartline Investment Corp now owns 21,934 shares of the company’s stock worth $12,786,000 after acquiring an additional 248 shares during the period. Finally, Meritage Portfolio Management lifted its holdings in Eli Lilly and Company by 23.4% in the fourth quarter. Meritage Portfolio Management now owns 6,377 shares of the company’s stock valued at $3,717,000 after acquiring an additional 1,208 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Up 6.0 %

Shares of NYSE LLY traded up $44.36 during trading on Tuesday, hitting $781.56. 7,432,651 shares of the company traded hands, compared to its average volume of 3,071,009. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The firm has a market capitalization of $742.61 billion, a P/E ratio of 134.43, a P/E/G ratio of 1.60 and a beta of 0.34. The company has a 50-day moving average price of $760.89 and a 200-day moving average price of $668.00. Eli Lilly and Company has a 1 year low of $392.26 and a 1 year high of $800.78.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The company had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. During the same period in the prior year, the firm posted $2.09 earnings per share. The firm’s revenue was up 28.1% on a year-over-year basis. On average, equities analysts predict that Eli Lilly and Company will post 12.51 EPS for the current year.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on LLY shares. Bank of America increased their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a report on Friday, March 1st. TheStreet upgraded Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. BMO Capital Markets raised their price target on Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. JPMorgan Chase & Co. boosted their price objective on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. Finally, Morgan Stanley raised their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a report on Friday, February 16th. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $731.55.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.